FDA Inspection 1153168 — Jie Li
The FDA completed an inspection of Jie Li on July 30, 2021 in Beijing. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- July 30, 2021
- Fiscal Year
- 2021
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Beijing (China)
Additional Details
Clinical Investigator (CI)